Company Overview
Company Type: Public Company
Website: www.avicanna.com
Number of Employees: 80
Ticker: AVCN (TSX)
Year Founded: 2016


Business Description
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
6.4
Market Capitalization
38.5
TEV/Total Revenue
6.9x
EBITDA
(11.1)
Total Enterprise Value
44.1
TEV/EBITDA
NM
EBIT
(11.5)
Cash & ST Invst.
0.1
P/Diluted EPS Before Extra
NM
Net Income
(13.7)
Total Debt
1.8
Price/Tang BV
38.4x
Capital Expenditure
(0.1)
Total Assets
22.1
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023

Key Professionals
Name
Title
Azadian, Aras 
Co-Founder, CEO & Director
Cardella, Phillip 
Chief Financial Officer
Moghani, Arash 
Executive Vice President of Operations & Technology
Diaz, Ingrid 
VP, Assistant General Counsel & Corporate Compliance Officer
Maric, Ivana 
Executive Vice President of Marketing
Pujol, Enric 
Vice President of People
Devedec, Frantz Le
Executive Vice President of Research & Development
Kim, Stephen 
Chief Legal Officer & General Counsel of Avicanna USA Inc.
Muete, Carlos Enrique Maldonado
SVP of Clinical Development
Urban, Karolina 
Executive Vice President of Scientific & Medical Affairs

Key Board Members
Name
Title
Azadian, Aras 
Co-Founder, CEO & Director
McCormack, Eileen 
Independent Director
McVicar, John 
Independent Director
Char, Giancarlo Davila
Director
Harrington, Al 
Member of Business Advisory Board
Hobson, Jason A.
Member of Business Advisory Board
Inwentash, Sheldon 
Member of Business Advisory Board
Jones, Max 
Member of Global Scientific Advisory Board
Masuda, Aline D.
Member of Business Advisory Board
Reynales, Humberto 
Member of International Scientific Advisory Board
Sauder, Daniel N.
Member of Global Scientific Advisory Board
Tal, Ori 
Member of Business Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
480 University Avenue Suite 1502 | Toronto, ON | M5G 1V2 | Canada

Current and Pending Investors
Barn Investimentos, Ei.Ventures, Inc., Plant-Based Investment Corp. (OTCPK:CWWB.F), Plaza Capital Ltd., Tasly International Capital Limited, ThreeD Capital Inc. (CNSX:IDK)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.49
Market Cap (mm)
42.9
Open
 0.44
Shares Out. (mm)
87.5
Previous Close
 0.49
Float %
80.0%
Change on Day
0.05
Shares Sold Short (mm)
-
Change % on Day
11.4%
Dividend Yield %
-
Day High/Low
 0.49/ 0.44
Diluted EPS Excl. Extra Items
(0.19)
52 wk High/Low
 0.56/ 0.23
P/Diluted EPS Before Extra
NM
Volume (mm)
0.18
Avg 3M Dly Vlm (mm)
0.26
Beta 5Y
1.60


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:AVCN - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Medical Cannabis by Shoppers Drug Mart Inc
Medical Cannabis by Shoppers Drug Mart Inc retails medical cannabis through the internet. The company was incorporated in 2015 and is based in Mississauga, Canada. Medical Cannabis by Shoppers Drug Mart Inc operates as a subsidiary of Shoppers Drug Mart Inc. As of August 1, 2023, Medical Cannabis by Shoppers Drug Mart Inc operates as a subsidiary of Avicanna Inc.

United States and Canada
Other Specialty Retail
-
-
-
Santa Marta Golden Hemp S.A.S.
Santa Marta Golden Hemp S.A.S. cultivates medical cannabis in Colombia. The company is based in Santa Marta, Colombia. As of October 22, 2018, Santa Marta Golden Hemp S.A.S. operates as a subsidiary of Avicanna Inc.

Latin America and Caribbean
Pharmaceuticals
-
-
-
2516167 Ontario Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-02-2023
Aug-02-2023
Private Placement
Target
Avicanna Inc. (TSX:AVCN)


1.09
May-29-2023
Aug-01-2023
Merger/Acquisition
Buyer
Medical Cannabis by Shoppers Drug Mart Inc
Avicanna Inc. (TSX:AVCN)
Shoppers Drug Mart Inc.
-
Mar-21-2023
Mar-21-2023
Private Placement
Target
Avicanna Inc. (TSX:AVCN)


0.90
Dec-21-2022
Dec-21-2022
Private Placement
Target
Avicanna Inc. (TSX:AVCN)


1.30
Nov-11-2022
Nov-11-2022
Private Placement
Target
Avicanna Inc. (TSX:AVCN)


0.47
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-01-2023
Executive/Board Changes - Other
Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors
Aug-14-2023
Product-Related Announcements
Avicanna Inc. Announces Launch of an All-New Medical Cannabis Care Platform, MyMedi.Ca
Aug-02-2023
Private Placements
Avicanna Inc. announced that it has received CAD 1.455 million in funding
Aug-01-2023
M&A Transaction Closings
Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.
Jun-28-2023
Special Calls
Avicanna Inc. - Special Call

M&A Advisors
Bayline Capital Partners Inc.


Advisors
Most Recent Auditor
Kingston Ross Pasnak LLP
M&A Advisors
Bayline Capital Partners Inc.
Private Placement Advisors
Canaccord Genuity Group Inc. (TSX:CF), Paradigm Capital Inc., Sprott Private Wealth LP
Public Offering Advisors
DLA Piper (Canada) LLP, MNP LLP


Most Recent Auditor
Kingston Ross Pasnak LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:16 AM
AVCN
Avicanna Inc 2023_10_05
Reports
15
S&P Global Compustat

Sep 07, 2023 04:15 AM
AVCN
Avicanna Inc 2023_09_07
Reports
15
S&P Global Compustat

Jul 06, 2023 03:35 AM
AVCN
Avicanna Inc 2023_07_06
Reports
15
S&P Global Compustat

Jun 01, 2023 04:38 AM
AVCN
Avicanna Inc 2023_06_01
Reports
15
Wright Investors' Service Inc.

May 24, 2023 01:46 AM
AVCN
Flow of Funds Report for Avicanna Inc - prepared by Wright Investors Service
Notes
66
S&P Global Compustat

May 04, 2023 03:59 AM
AVCN
Avicanna Inc 2023_05_04
Reports
15
S&P Global Compustat

Apr 06, 2023 04:15 AM
AVCN
Avicanna Inc 2023_04_06
Reports
14
S&P Global Compustat

Mar 02, 2023 03:54 AM
AVCN
Avicanna Inc 2023_03_02
Reports
14
S&P Global Compustat

Feb 02, 2023 03:37 AM
AVCN
Avicanna Inc 2023_02_02
Reports
14
S&P Global Compustat

Jan 05, 2023 03:59 AM
AVCN
Avicanna Inc 2023_01_05
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Inwentash B.Com., B.Comm., C.A., CPA, CA., CPA, LL.D. (Ho, Sheldon 

5,157,550

5.89

2.3

Aug-02-2023


ThreeD Capital Inc.

5,148,300

5.88

2.3

Jun-19-2023


Azadian B.Econ, Mba, Aras 

3,553,927

4.06

1.6

Apr-10-2023


El Grupo Daabon

1,477,818

1.69

0.7

Apr-10-2023


Nosiglia MBA, Lucas 

590,439

0.67

0.3

Apr-21-2022


Siranom Investment Inc.

363,202

0.42

0.2

Apr-10-2023


Cardella C.A., CPA, Phillip 

326,326

0.37

0.1

Jun-23-2023


Panchal M.Sc., Ph.D., Chandrakant J.

291,959

0.33

0.1

Apr-10-2023


Char, Giancarlo Davila

233,424

0.27

0.1

Apr-10-2023


McVicar, John 

207,804

0.24

0.1

Jun-21-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Azadian B.Econ, Mba, Aras 
3,553,927
763,878
ThreeD Capital Inc.
5,148,300
425,000
Cardella C.A., CPA, Phillip 
326,326
166,561
Panchal M.Sc., Ph.D., Chandrakant J.
291,959
109,078
McVicar, John 
207,804
94,603

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Anti-Aging Cream (Future), AVCN319301 (Future), AVCN467501 (Future), AVCN583301 (Future), AVCN583601 (Future), AVCN585501 (Future), AVCN771201 (Future), Blemishes Cream (Future), Body Lotion (Future), Clarifying Cream (Future), Clear Skin Gel (Future), Eye Contour Cream (Future), Facial Lotion (Future), Intensive Emollient Cream (Future), Intensive Moisturizing Cream (Future), Medical Cannabis, Micro Drops (Future), MyMedi.ca, Rapid Act Sprays (Future), RHO Phyto Deep Tissue Gels (Future), Sales of Coolers, Sales of Staples, Topical Serum (Future)


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-01-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
82 KB
Aug-15-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
87 KB
Aug-14-2023
Jun-30-2023
Avicanna Inc. (TSX:AVCN)
SEDAR
Interim Financial Statements
697 KB
Aug-14-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
41 KB
Aug-14-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
135 KB
Aug-10-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
Material Change Report
4 KB
Jul-17-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
216 KB
Jun-28-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
92 KB
Jun-26-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
199 KB
Jun-22-2023
-
Avicanna Inc. (TSX:AVCN)
SEDAR
News Releases
145 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Cardella C.A., CPA, Phillip  (Chief Financial Officer)
Jun-23-2023
Common Shares
48,152
15,059
Derivative Exercise and Retained Stock
17.31
Multiple
McVicar, John  (Independent Director)
Jun-21-2023
Common Shares
78,642
0
Derivative Exercise and Retained Stock
60.89
Multiple
ThreeD Capital Inc.
Jun-19-2023
Common Shares
425,000
176,071
Derivative Exercise and Retained Stock
9.00
Multiple
Cardella C.A., CPA, Phillip  (Chief Financial Officer)
Jun-01-2023
Common Shares
28,570
10,156
Derivative Exercise and Retained Stock
11.45
Multiple
McVicar, John  (Independent Director)
Apr-12-2023
Common Shares
15,961
-
Derivative Exercise and Retained Stock
14.10
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Azadian, Aras 
Co-Founder, CEO & Director
-
-

McCormack, Eileen 
Independent Director
-
-

McVicar, John 
Independent Director
-
-

Char, Giancarlo Davila
Director
-
-

Harrington, Al 
Member of Business Advisory Board
-
-

Hobson, Jason A.
Member of Business Advisory Board
-
-
jason@ei.ventures.com
Inwentash, Sheldon 
Member of Business Advisory Board
-
-

Jones, Max 
Member of Global Scientific Advisory Board
-
-

Masuda, Aline D.
Member of Business Advisory Board
-
-

Reynales, Humberto 
Member of International Scientific Advisory Board
-
-
-
Sauder, Daniel N.
Member of Global Scientific Advisory Board
-
-
-
Tal, Ori 
Member of Business Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Azadian, Aras 
Co-Founder, CEO & Director
-
-

Cardella, Phillip 
Chief Financial Officer
-
-

Moghani, Arash 
Executive Vice President of Operations & Technology
-
-

Diaz, Ingrid 
VP, Assistant General Counsel & Corporate Compliance Officer
-
-

Maric, Ivana 
Executive Vice President of Marketing
-
-
-
Pujol, Enric 
Vice President of People
-
-

Devedec, Frantz Le
Executive Vice President of Research & Development
-
-

Kim, Stephen 
Chief Legal Officer & General Counsel of Avicanna USA Inc.
-
-

Muete, Carlos Enrique Maldonado
SVP of Clinical Development
-
-
-
Urban, Karolina 
Executive Vice President of Scientific & Medical Affairs
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
